Multiple Sclerosis, Relapsing-Remitting Clinical Trial
— SONICSOfficial title:
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Verified date | August 2023 |
Source | University of Texas Southwestern Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Central Nervous System (CNS) demyelinating conditions include multiple sclerosis (MS), Acute Disseminated Encephalomyelitis (ADEM), Neuromyelitis Optica Spectrum Disorder (NMOSD), Optic Neuritis (ON) and Transverse Myelitis (TM). The symptoms of these conditions are quite variable from patient to patient, but can include motor, sensory, visual, gait and cognitive changes. Conventional MRI can be used to look for new anatomic changes, but fails to measure underlying biochemical changes in brain tissue. The purposes of this study are to identify the biologic and anatomic correlations between cognitive profiles and disease activity using MRI imaging techniques.
Status | Completed |
Enrollment | 49 |
Est. completion date | June 30, 2023 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Years to 21 Years |
Eligibility | Inclusion Criteria: 1. Diagnosis of Multiple Sclerosis , ADEM, anti-MOG antibody associated CNS demyelination 2. Age 12 to 21 inclusive at time of enrollment 3. Ability of parent or legal guardian to provide informed consent if participant is under 18. 4. Ability of patients age 12-17 to give assent 5. Completion of the signed HIPPA authorization form by a parent or legal guardian or by participants (18 years of age). Exclusion Criteria: 1. Known history of traumatic brain injury that required medical care 2. Non-English speaking (based on standardized neuropsychological testing and questionnaires) 3. Claustrophobic, the presence of metallic braces, implants or medical devices that are unsafe at 3T or 7T and/or interfere with the MRI/MRS signals |
Country | Name | City | State |
---|---|---|---|
United States | University Texas Southwestern | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MRI Brain without contrast | 3T MRI | 10-14 months | |
Primary | MRI Brain without contrast | 7T MRI | 10-14 months | |
Primary | Change in Score of Delis-Kaplan Executive Function System (D-KEFS) Color | Executive Functioning | 10-14 months | |
Primary | Change in Score of Word Interference Test (CWIT) | Executive Functioning | 10-14 months | |
Primary | Change in Score of Symbol Digit Modalities (SDMT)- Oral Version | Processing Speed | 10-14 months | |
Primary | Change in Score of Beery-Buktencia Developmental Test of Visual-Motor Integration, Sixth Edition (VMI-6) | Visual-Motor Integration | 10-14 months | |
Primary | Change in Score of Wechsler Intelligence Scale for Children-5th edition (WISCV) | Simple Auditory Attention | 10-14 months | |
Primary | Change in Score of Wechsler Adult Intelligence Scale-Fourth edition (WAIS-IV) Digits Forward | Simple Auditory Attention | 10-14 months | |
Primary | Change in Score of WISC-V or WAIS-IV Digits Backward | Working Memory | 10-14 months | |
Primary | Change in Score of California Verbal Learning Test- Children's Version (CVLT-C) or California Verbal Learning Test-Second Edition (CVLT-II) | Verbal Learning and Memory | 10-14 months | |
Primary | Change i Score of D-KEFS Letter and Category Fluency | Verbal Fluency | 10-14 months | |
Primary | Change in Score of WASI-II | Estimate of IQ | 10-14 months | |
Primary | Change in Score of Woodcock-Johnson Tests of Achievement Letter Word identification | Basic Reading Skill | 10-14 months | |
Primary | Change in Score of Reading Fluency | Reading Speed | 10-14 months | |
Primary | Change in Score of Calculation | Math Calculation Skills | 10-14 months | |
Primary | Change in Score of Math Fluency | Math Speed | 10-14 months | |
Primary | Change in Score of Word Attack | Phoneme/Grapheme Knowledge | 10-14 months | |
Primary | Change in Score of Grooved Pegboard | Bilateral Fine Motor Speed and Dexterity | 10-14 months | |
Primary | Change in Score of Trail Making Test, Part A and B | Simple and complex Attention | 10-14 months | |
Primary | Change in Score of Conners Continuous Performance Test 3rd Edition | Sustained Attention and Behavioral Inhibition | 10-14 months | |
Secondary | Change in Examination of Optical Coherence Tomography | Eye examination | 10-14 months | |
Secondary | Change in PROMIS Mobility score | Patient Reported Outcomes Measures: Mobility, walking | 10-14 months | |
Secondary | Change in PROMIS Pain score | Patient Reported Outcomes Measures: overall pain level | 10-14 months | |
Secondary | Change in PROMIS Peer relationship score | Patient Reported Outcomes Measures: Peer relationships | 10-14 months | |
Secondary | Change in PROMIS Stress score | Patient Reported Outcomes Measures: Psychological stress | 10-14 months | |
Secondary | Change in PROMIS Upper extremity movement score | Patient Reported Outcomes Measures: Upper extremity movement | 10-14 months | |
Secondary | Change in score of 25 foot timed walk | Walking speed | 10-14 months | |
Secondary | Change in score of 6 minute timed walk | Walking Distance | 10-14 months | |
Secondary | Change in score of Hauser Ambulation Index | Functional walking assessment | 10-14 months | |
Secondary | Change in score of Multiple Sclerosis Functional Capacity (MSFC) | Hand and Eye coordination, Memory test | 10-14 months | |
Secondary | Change in score of Modified Rankin Scale | Disability scale | 10-14 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02861014 -
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
|
Phase 3 | |
Terminated |
NCT01435993 -
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
|
Phase 1 | |
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02410200 -
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
|
Phase 2 | |
Completed |
NCT03975413 -
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
|
||
Completed |
NCT05080270 -
Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis
|
Early Phase 1 | |
Completed |
NCT01116427 -
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01108887 -
An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmartâ„¢.
|
N/A | |
Completed |
NCT01141751 -
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
|
N/A | |
Completed |
NCT00097331 -
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01909492 -
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
|
||
Completed |
NCT04121221 -
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
|
Phase 3 | |
Withdrawn |
NCT04880577 -
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT05290688 -
Cellular microRNA Signatures in Multiple Sclerosis
|
N/A | |
Completed |
NCT04528121 -
Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT04002934 -
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT05019248 -
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
|
||
Completed |
NCT04580381 -
Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
|
||
Completed |
NCT00071838 -
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 2 |